Abstract
Vitamin K antagonist (VKA) therapy is a mainstay of treatment for patients at risk of thromboembolic events. Despite widespread use, a major limitation of VKA therapy is the substantial risk of serious bleeding complications, which often require rapid reversal of anticoagulation. A recent randomized multicenter comparison between a 4-factor prothrombin complex concentrate (4F-PCC) and plasma in patients with acute major bleeding has provided important new evidence of the benefit of 4F-PCC over plasma for urgent VKA reversal.
Original language | English (US) |
---|---|
Pages (from-to) | 613-621 |
Number of pages | 9 |
Journal | Clinics in laboratory medicine |
Volume | 34 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1 2014 |
Keywords
- Anticoagulants
- Hemorrhage
- Plasma
- Prothrombin complex concentrates
- Vitamin K antagonist
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical